Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.

Gerusz V, Denis A, Faivre F, Bonvin Y, Oxoby M, Briet S, LeFralliec G, Oliveira C, Desroy N, Raymond C, Peltier L, Moreau F, Escaich S, Vongsouthi V, Floquet S, Drocourt E, Walton A, Prouvensier L, Saccomani M, Durant L, Genevard JM, Sam-Sambo V, Soulama-Mouze C.

J Med Chem. 2012 Nov 26;55(22):9914-28. doi: 10.1021/jm301113w. Epub 2012 Oct 23.

PMID:
23092194
2.

Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.

Takahata S, Iida M, Yoshida T, Kumura K, Kitagawa H, Hoshiko S.

J Antibiot (Tokyo). 2007 Feb;60(2):123-8.

PMID:
17420562
3.

Potent antimicrobial action of triclosan-lysozyme complex against skin pathogens mediated through drug-targeted delivery mechanism.

Hoq MI, Ibrahim HR.

Eur J Pharm Sci. 2011 Jan 18;42(1-2):130-7. doi: 10.1016/j.ejps.2010.11.002. Epub 2010 Nov 13.

PMID:
21078387
4.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820
5.

Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA).

Brenwald NP, Fraise AP.

J Hosp Infect. 2003 Oct;55(2):141-4.

PMID:
14529640
6.

Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.

Massengo-Tiassé RP, Cronan JE.

J Biol Chem. 2008 Jan 18;283(3):1308-16. Epub 2007 Nov 21.

7.

Design, development, synthesis, and docking analysis of 2'-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase.

Kapoor N, Banerjee T, Babu P, Maity K, Surolia N, Surolia A.

IUBMB Life. 2009 Nov;61(11):1083-91. doi: 10.1002/iub.258.

8.
9.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF.

J Med Chem. 2003 Apr 24;46(9):1627-35.

PMID:
12699381
11.

Signature gene expression profile of triclosan-resistant Escherichia coli.

Yu BJ, Kim JA, Pan JG.

J Antimicrob Chemother. 2010 Jun;65(6):1171-7. doi: 10.1093/jac/dkq114. Epub 2010 Apr 21.

PMID:
20410062
12.

Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.

Priyadarshi A, Kim EE, Hwang KY.

Proteins. 2010 Feb 1;78(2):480-6. doi: 10.1002/prot.22581. No abstract available.

PMID:
19768684
13.

Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus.

Fan F, Yan K, Wallis NG, Reed S, Moore TD, Rittenhouse SF, DeWolf WE Jr, Huang J, McDevitt D, Miller WH, Seefeld MA, Newlander KA, Jakas DR, Head MS, Payne DJ.

Antimicrob Agents Chemother. 2002 Nov;46(11):3343-7.

14.

Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis.

Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO.

J Biol Chem. 1998 Nov 13;273(46):30316-20.

15.

Characterization of a novel enoyl-acyl carrier protein reductase of diazaborine-resistant Rhodobacter sphaeroides mutant.

Lee IH, Kim EJ, Cho YH, Lee JK.

Biochem Biophys Res Commun. 2002 Dec 13;299(4):621-7.

PMID:
12459184
16.

Mechanism of triclosan inhibition of bacterial fatty acid synthesis.

Heath RJ, Rubin JR, Holland DR, Zhang E, Snow ME, Rock CO.

J Biol Chem. 1999 Apr 16;274(16):11110-4.

17.

Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.

Sivaraman S, Sullivan TJ, Johnson F, Novichenok P, Cui G, Simmerling C, Tonge PJ.

J Med Chem. 2004 Jan 29;47(3):509-18.

PMID:
14736233
18.

Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Cheng G, Muench SP, Zhou Y, Afanador GA, Mui EJ, Fomovska A, Lai BS, Prigge ST, Woods S, Roberts CW, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Rice DW, McLeod R.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2035-43. doi: 10.1016/j.bmcl.2013.02.019. Epub 2013 Feb 13.

19.

Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Moir DT.

Curr Drug Targets Infect Disord. 2005 Sep;5(3):297-305. Review.

PMID:
16181147
20.

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf Jr WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF.

Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24.

Supplemental Content

Support Center